Hypothalamic involvement in the activation of the pituitary-adrenocortical axis by nerve growth factor

S. Scaccianoce, G. Cigliana, R. Nicolai, L. A A Muscolo, A. Porcu, D. Navarra, J. R. Perez-Polo, L. Angelucci

    Research output: Contribution to journalArticle

    45 Citations (Scopus)

    Abstract

    Intravenous injection of nerve growth factor (NGF) into rats produces a dosedependent (from 0.1 to 5 nmol/kg) increase in circulating concentrations of adrenocoticotropin (ACTH) and corticosterone. We have investigated whether this effect is produced through a direct action on a component of the hypothalamo-pituitary-adrenocortical axis. NGF (50 and 500 nM), added to the incubation medium of in vitro isolated pituitary segments or dispersed adrenal cells, did not modify either basal and stimulated release of biologically active or immunoreactive ACTH or release of corticosterone, respectively. The presence of NGF in the incubation medium of in vitro isolated hypothalami produced a dose-dependent (from 150 to 600 nM) increase of both release and content of some material with corticotropin-releasing bioactivity. The nature of this corticotropin-releasing bioactivity was determined directly by radioimmunoassays. Results have indicated that NGF induced an increase of both release and content of hypothalamic arginine-vasopressin (AVP), while no changes were observed in the release and content of hypothalamic corticotropin-releasing hormone (CRH). These results suggest that adrenocortical stimulation by NGF in vivo could be mediated by the release of hypothalamic AVP rather than CRH. The finding that in vivo NGF stimulatory effect was not abolished by the specific CRH antagonist a-helical CRH(9-41), while it was accompanied by an increase in circulating AVP levels, supports this interpretation. However, the fact that the hypothalamus is stimulated in vitro by NGF concentrations higher than those expected to reach this structure after systemic injection of active doses raises the possibility that other brain areas such as the hippocampus participate in NGF-induced adrenocortical activation.

    Original languageEnglish (US)
    Pages (from-to)202-209
    Number of pages8
    JournalNeuroendocrinology
    Volume58
    Issue number2
    StatePublished - 1993

    Fingerprint

    Nerve Growth Factor
    Adrenocorticotropic Hormone
    Arginine Vasopressin
    Corticotropin-Releasing Hormone
    Corticosterone
    Hypothalamus
    Pituitary Hormone-Releasing Hormones
    Hormone Antagonists
    Intravenous Injections
    Radioimmunoassay
    Hippocampus
    Injections
    Brain
    In Vitro Techniques

    Keywords

    • Corticosterone
    • CRH, ACTH
    • Hypothalamus
    • NGF
    • Stress, rat
    • Vasopressin

    ASJC Scopus subject areas

    • Endocrinology
    • Neuroscience(all)

    Cite this

    Scaccianoce, S., Cigliana, G., Nicolai, R., Muscolo, L. A. A., Porcu, A., Navarra, D., ... Angelucci, L. (1993). Hypothalamic involvement in the activation of the pituitary-adrenocortical axis by nerve growth factor. Neuroendocrinology, 58(2), 202-209.

    Hypothalamic involvement in the activation of the pituitary-adrenocortical axis by nerve growth factor. / Scaccianoce, S.; Cigliana, G.; Nicolai, R.; Muscolo, L. A A; Porcu, A.; Navarra, D.; Perez-Polo, J. R.; Angelucci, L.

    In: Neuroendocrinology, Vol. 58, No. 2, 1993, p. 202-209.

    Research output: Contribution to journalArticle

    Scaccianoce, S, Cigliana, G, Nicolai, R, Muscolo, LAA, Porcu, A, Navarra, D, Perez-Polo, JR & Angelucci, L 1993, 'Hypothalamic involvement in the activation of the pituitary-adrenocortical axis by nerve growth factor', Neuroendocrinology, vol. 58, no. 2, pp. 202-209.
    Scaccianoce S, Cigliana G, Nicolai R, Muscolo LAA, Porcu A, Navarra D et al. Hypothalamic involvement in the activation of the pituitary-adrenocortical axis by nerve growth factor. Neuroendocrinology. 1993;58(2):202-209.
    Scaccianoce, S. ; Cigliana, G. ; Nicolai, R. ; Muscolo, L. A A ; Porcu, A. ; Navarra, D. ; Perez-Polo, J. R. ; Angelucci, L. / Hypothalamic involvement in the activation of the pituitary-adrenocortical axis by nerve growth factor. In: Neuroendocrinology. 1993 ; Vol. 58, No. 2. pp. 202-209.
    @article{e279e30db9bf46529de051ad3da761d7,
    title = "Hypothalamic involvement in the activation of the pituitary-adrenocortical axis by nerve growth factor",
    abstract = "Intravenous injection of nerve growth factor (NGF) into rats produces a dosedependent (from 0.1 to 5 nmol/kg) increase in circulating concentrations of adrenocoticotropin (ACTH) and corticosterone. We have investigated whether this effect is produced through a direct action on a component of the hypothalamo-pituitary-adrenocortical axis. NGF (50 and 500 nM), added to the incubation medium of in vitro isolated pituitary segments or dispersed adrenal cells, did not modify either basal and stimulated release of biologically active or immunoreactive ACTH or release of corticosterone, respectively. The presence of NGF in the incubation medium of in vitro isolated hypothalami produced a dose-dependent (from 150 to 600 nM) increase of both release and content of some material with corticotropin-releasing bioactivity. The nature of this corticotropin-releasing bioactivity was determined directly by radioimmunoassays. Results have indicated that NGF induced an increase of both release and content of hypothalamic arginine-vasopressin (AVP), while no changes were observed in the release and content of hypothalamic corticotropin-releasing hormone (CRH). These results suggest that adrenocortical stimulation by NGF in vivo could be mediated by the release of hypothalamic AVP rather than CRH. The finding that in vivo NGF stimulatory effect was not abolished by the specific CRH antagonist a-helical CRH(9-41), while it was accompanied by an increase in circulating AVP levels, supports this interpretation. However, the fact that the hypothalamus is stimulated in vitro by NGF concentrations higher than those expected to reach this structure after systemic injection of active doses raises the possibility that other brain areas such as the hippocampus participate in NGF-induced adrenocortical activation.",
    keywords = "Corticosterone, CRH, ACTH, Hypothalamus, NGF, Stress, rat, Vasopressin",
    author = "S. Scaccianoce and G. Cigliana and R. Nicolai and Muscolo, {L. A A} and A. Porcu and D. Navarra and Perez-Polo, {J. R.} and L. Angelucci",
    year = "1993",
    language = "English (US)",
    volume = "58",
    pages = "202--209",
    journal = "Neuroendocrinology",
    issn = "0028-3835",
    publisher = "S. Karger AG",
    number = "2",

    }

    TY - JOUR

    T1 - Hypothalamic involvement in the activation of the pituitary-adrenocortical axis by nerve growth factor

    AU - Scaccianoce, S.

    AU - Cigliana, G.

    AU - Nicolai, R.

    AU - Muscolo, L. A A

    AU - Porcu, A.

    AU - Navarra, D.

    AU - Perez-Polo, J. R.

    AU - Angelucci, L.

    PY - 1993

    Y1 - 1993

    N2 - Intravenous injection of nerve growth factor (NGF) into rats produces a dosedependent (from 0.1 to 5 nmol/kg) increase in circulating concentrations of adrenocoticotropin (ACTH) and corticosterone. We have investigated whether this effect is produced through a direct action on a component of the hypothalamo-pituitary-adrenocortical axis. NGF (50 and 500 nM), added to the incubation medium of in vitro isolated pituitary segments or dispersed adrenal cells, did not modify either basal and stimulated release of biologically active or immunoreactive ACTH or release of corticosterone, respectively. The presence of NGF in the incubation medium of in vitro isolated hypothalami produced a dose-dependent (from 150 to 600 nM) increase of both release and content of some material with corticotropin-releasing bioactivity. The nature of this corticotropin-releasing bioactivity was determined directly by radioimmunoassays. Results have indicated that NGF induced an increase of both release and content of hypothalamic arginine-vasopressin (AVP), while no changes were observed in the release and content of hypothalamic corticotropin-releasing hormone (CRH). These results suggest that adrenocortical stimulation by NGF in vivo could be mediated by the release of hypothalamic AVP rather than CRH. The finding that in vivo NGF stimulatory effect was not abolished by the specific CRH antagonist a-helical CRH(9-41), while it was accompanied by an increase in circulating AVP levels, supports this interpretation. However, the fact that the hypothalamus is stimulated in vitro by NGF concentrations higher than those expected to reach this structure after systemic injection of active doses raises the possibility that other brain areas such as the hippocampus participate in NGF-induced adrenocortical activation.

    AB - Intravenous injection of nerve growth factor (NGF) into rats produces a dosedependent (from 0.1 to 5 nmol/kg) increase in circulating concentrations of adrenocoticotropin (ACTH) and corticosterone. We have investigated whether this effect is produced through a direct action on a component of the hypothalamo-pituitary-adrenocortical axis. NGF (50 and 500 nM), added to the incubation medium of in vitro isolated pituitary segments or dispersed adrenal cells, did not modify either basal and stimulated release of biologically active or immunoreactive ACTH or release of corticosterone, respectively. The presence of NGF in the incubation medium of in vitro isolated hypothalami produced a dose-dependent (from 150 to 600 nM) increase of both release and content of some material with corticotropin-releasing bioactivity. The nature of this corticotropin-releasing bioactivity was determined directly by radioimmunoassays. Results have indicated that NGF induced an increase of both release and content of hypothalamic arginine-vasopressin (AVP), while no changes were observed in the release and content of hypothalamic corticotropin-releasing hormone (CRH). These results suggest that adrenocortical stimulation by NGF in vivo could be mediated by the release of hypothalamic AVP rather than CRH. The finding that in vivo NGF stimulatory effect was not abolished by the specific CRH antagonist a-helical CRH(9-41), while it was accompanied by an increase in circulating AVP levels, supports this interpretation. However, the fact that the hypothalamus is stimulated in vitro by NGF concentrations higher than those expected to reach this structure after systemic injection of active doses raises the possibility that other brain areas such as the hippocampus participate in NGF-induced adrenocortical activation.

    KW - Corticosterone

    KW - CRH, ACTH

    KW - Hypothalamus

    KW - NGF

    KW - Stress, rat

    KW - Vasopressin

    UR - http://www.scopus.com/inward/record.url?scp=0027380033&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0027380033&partnerID=8YFLogxK

    M3 - Article

    VL - 58

    SP - 202

    EP - 209

    JO - Neuroendocrinology

    JF - Neuroendocrinology

    SN - 0028-3835

    IS - 2

    ER -